We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Genetic Factors Involved in Sudden Unexpected Death in Children

By LabMedica International staff writers
Posted on 29 Apr 2021
Image: New genetic factors involved in Sudden Unexpected Death in Pediatrics (SUDP) have been revealed by combining exome sequencing analysis with detailed phenotyping (Photo courtesy of Boston Children`s Hospital)
Image: New genetic factors involved in Sudden Unexpected Death in Pediatrics (SUDP) have been revealed by combining exome sequencing analysis with detailed phenotyping (Photo courtesy of Boston Children`s Hospital)
About 10% of deaths in infants and children occur suddenly and have no apparent cause. Sudden Unexpected Death in Pediatrics (SUDP) encompasses several related phenomena, including Sudden Infant Death Syndrome (SIDS), Sudden Unexplained Death in Childhood (SUDC), and Sudden Unexpected Infant Death (SUID).

The most widely accepted explanation for these unexplained deaths, is that children with an intrinsic, or genetic, predisposition experience some sort of extrinsic risk, such as soft bedding or a certain sleep position, during a critical period of their development. A new study has found several genes with functions in neurological disease or systemic/syndromic conditions that had not previously been implicated in the SUDP.

Medical Scientists at the Boston Children's Hospital (Boston, MA, USA) and their colleagues surveyed a total of 352 SUDP cases, including 73 with parental samples. The age of death in these children ranged from one day to 11 years, with an average of six months, and the team obtained detailed phenotypic descriptions for them. The investigators conducted exome sequencing and analyzed the data for rare damaging variants in genes involved in neurological, cardiac, and systemic or syndromic disease mechanisms, a list of 294 potential SUDP genes. They classified variants as pathogenic, likely pathogenic, and variants of uncertain significance (VUS) and introduced an additional category, called VUS-favor pathogenic (VUS-FP).

In a proband-only analysis, they identified 109 rare damaging variants in 98 probands, or 28% of which 12 were classified as pathogenic or likely pathogenic and 17 as VUS-FP. This was a higher burden of such variants than in healthy controls. In addition, an analysis of the parent-proband exome data uncovered 51 de novo variants, of which eight were classified as pathogenic/likely pathogenic or VUS-FP, as well as 13 X-linked maternally inherited variants. A burden analysis found that SUDP trios had almost three times more rare damaging de novo variants than controls, suggesting that these variants play a causal role.

Overall, the scientists identified 38 rare damaging variants, 16 pathogenic or likely pathogenic and 22 VUS-FP variants in the SUDP cases, accounting for 11% of all cases. Of those, 14 were in neurological, 18 in cardiac, and six in systemic/syndromic disease genes. Variants in cardiac disease genes all occurred in children who died within their first year of life.

The authors concluded that their results suggest that genetic factors play an important role in SUDP. The findings can provide bereaved parents with an explanation of why their child died, help identify at-risk family members, and lead to counseling about recurrence risk. The study was presented at the American College of Medical Genetics and Genomics annual clinical meeting held virtually on 13-16 April, 2021.

Related Links:
Boston Children's Hospital

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.

Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more